These tests help detect genetic and chromosomal abnormalities, such as Down syndrome, neural tube defects, and other inherited conditions, through markers like hormone levels or fetal DNA in the mother’s blood. Non-invasive and highly informative, tests such as the Double Marker, Triple Marker, Quadruple Marker, and NIPT provide early insights that support informed decision-making and timely medical care throughout pregnancy.
A blood test done in the first trimester to screen for chromosomal abnormalities like Down syndrome.
It measures levels of hCG and PAPP-A along with an NT scan.
Non-invasive and helps assess early risk for genetic conditions.
Performed in the second trimester, this test screens for neural tube defects and chromosomal abnormalities.
It measures AFP, hCG, and estriol levels in the mother’s blood.
Provides risk assessment for conditions like Down syndrome and spina bifida.
An advanced version of the triple marker test with the addition of inhibin A.
Offers improved accuracy in detecting chromosomal and neural tube defects.
Done between 15–22 weeks of pregnancy for better screening precision.
A highly accurate blood test that analyzes fetal DNA from the mother’s blood.
Screens for common chromosomal conditions like Down, Edwards, and Patau syndromes.
Safe, non-invasive, and can be done as early as 10 weeks of pregnancy.
An extended version of NIPT that screens for additional genetic conditions and microdeletions.
Provides a more comprehensive view of fetal chromosomal health.
Ideal for high-risk pregnancies or those seeking detailed genetic insights.
